CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −3,748 | 36,356 | ||
| 2025-12-01 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −4,000 | $29.30 | $117K | 65,740 |
| 2025-11-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 78,740 |
| 2025-11-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,000 | $30.38 | $273K | 69,740 |
| 2025-11-03 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 40,104 | ||
| 2025-10-15 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise 10b5-1 | +5,000 | $19.34 | $97K | 82,740 |
| 2025-10-15 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Sale 10b5-1 | −9,000 | $31.53 | $284K | 73,740 |
| 2025-10-15 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −5,000 | 45,104 | ||
| 2025-10-08 | Reed Joshua SVP, Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +158,743 | 158,743 | ||
| 2025-10-08 | Reed Joshua SVP, Chief Financial Officer | Grant or award · Restricted Stock Unit Award | +36,656 | 36,656 | ||
| 2025-08-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Option exercise | +2,014 | 206,269 | ||
| 2025-08-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Shares withheld for taxes | −895 | $26.55 | $24K | 205,374 |
| 2025-08-03 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Option exercise · Restricted Stock Unit Award | −2,014 | 2,015 | ||
| 2025-06-10 | Nichols Christian Todd SVP, Chief Commercial Officer | Sale 10b5-1 | −3,334 | $31.09 | $104K | 86,208 |
| 2025-06-09 | Nichols Christian Todd SVP, Chief Commercial Officer | Sale 10b5-1 | −3,333 | $31.95 | $106K | 89,542 |
| 2025-06-08 | Wright Christopher I Director | Option exercise | +3,301 | 23,806 | ||
| 2025-06-08 | Wright Christopher I Director | Shares withheld for taxes | −793 | $31.71 | $25K | 23,013 |
| 2025-06-08 | Wright Christopher I Director | Option exercise · Restricted Stock Unit Award | −3,301 | 0 | ||
| 2025-05-31 | Wright Christopher I Director | Option exercise | +8,013 | 22,429 | ||
| 2025-05-31 | Wright Christopher I Director | Shares withheld for taxes | −1,924 | $30.61 | $59K | 20,505 |
Page 11 of 41 · 804 trades